“It's very interesting to see how this continues to progress as a field,” says Kelly L. Stratton, MD FACS.
In this video, Kelly L. Stratton, MD, FACS, discusses the Kidney Cancer Course held during the 2022 Society of Urologic Oncology Annual Meeting. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.
The management of high-risk localized prostate cancer: Back to the future
April 5th 2024"I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state," writes Michael S. Cookson, MD, MMHC, FACS.
Subcutaneous nivolumab meets coprimary pharmacokinetic end points for ccRCC
January 30th 2024Patients in the subcutaneous arm (n = 242) achieved a geometric mean Cavgd28 of 77.373μl/mL (90% CI, 74.555-80.297) compared with 36.875 μl/mL (90% CI, 35.565-38.235) in the IV arm (n = 245), for a geometric mean ratio of 2.098 μl/mL (90% CI, 2.001-2.200).